K.Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 31 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.45 M
- Revenue Growth 82.02%
- Profit Growth 65.90%
- Ebitda 111.54%
- Net Worth 7.00%
- Total Assets 3.30%
About K.Pharmaceuticals
K.Pharmaceuticals Private Limited (KPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 July 1993 and has a history of 31 years and seven months. Its registered office is in Udaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.45 M.
Waseem Murtaza and Ahmed Faraz serve as directors at the Company.
Company Details
- Location
Udaipur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232RJ1993PTC007511
- Company No.
007511
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jul 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
What products or services does K.Pharmaceuticals Private Limited offer?
K.Pharmaceuticals Private Limited offers a wide range of products and services, including Product Development Research, Custom Synthesis Service.
Who are the key members and board of directors at K.Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Waseem Murtaza  | Director | 02-Jul-1993 | Current |
| Ahmed Faraz | Director | 19-Jan-2004 | Current |
Financial Performance of K.Pharmaceuticals.
K.Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 82.02% increase. The company also saw a substantial improvement in profitability, with a 65.9% increase in profit. The company's net worth moved up by a moderate rise of 7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of K.Pharmaceuticals?
In 2023, K.Pharmaceuticals had a promoter holding of 38.08% and a public holding of 61.92%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.45 M
₹0
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Sep 2006 | Indian Overseas Bank | ₹1.90 M | Open |
| 15 Sep 2006 | Indian Overseas Bank | ₹0.55 M | Open |
How Many Employees Work at K.Pharmaceuticals?
Unlock and access historical data on people associated with K.Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of K.Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped K.Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.